Amid questions being raised by industry experts and Opposition parties on the emergency approval granted to its coronavirus vaccine ‘Covaxin’ without publication of efficacy data, Bharat Biotech's chairman on Monday hit out at critics saying his firm had carried out "200 per cent honest clinical trials".